Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ERAS

Erasca Inc

Dec 10 • 04:00PM ET

2.96

Dollar change -0.02
Percentage change -0.67	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX ALNY RNA NTLA CRSP BEAM EDIT PFE AMGN

| Held by: VTI IWM VXF XBI IWN IBB SCHA VTWO VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.83	Insider Own	42.23%	Shs Outstand	282.69M	Perf Week	-3.58%
Market Cap	836.87M	Forward P/E	-	EPS next Y	-0.62	Insider Trans	0.00%	Shs Float	163.34M	Perf Month	-5.73%
Income	-159.12M	PEG	-	EPS next Q	-0.13	Inst Own	56.34%	Short Float	19.73%	Perf Quarter	-3.58%
Sales	0.00M	P/S	-	EPS this Y	10.10%	Inst Trans	12.82%	Short Ratio	18.05	Perf Half Y	31.56%
Book/sh	1.59	P/B	1.86	EPS next Y	16.55%	ROA	-33.56%	Short Interest	32.23M	Perf Year	58.29%
Cash/sh	1.13	P/C	2.62	EPS next 5Y	-4.10%	ROE	-40.33%	52W Range	1.64 - 3.45	Perf YTD	38.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-69.36%	ROI	-31.92%	52W High	-14.20%	Beta	1.19
Dividend TTM	-	Quick Ratio	11.00	Sales past 5Y	0.00%	Gross Margin	-	52W Low	80.49%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	11.00	EPS Y/Y TTM	51.10%	Oper. Margin	-	RSI (14)	52.48	Volatility	6.65% 7.78%
Employees	126	Debt/Eq	0.12	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.25	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	45.24%	Payout	-	Rel Volume	0.75	Prev Close	2.98
Sales Surprise	-	EPS Surprise	34.17%	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	1.79M	Price	2.96
SMA20	3.14%	SMA50	6.10%	SMA200	16.95%	Trades		Volume	1,349,197	Change	-0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Initiated	Jefferies	Buy	$6
Mar-11-24	Initiated	CapitalOne	Overweight	$8
Jan-05-24	Downgrade	BofA Securities	Buy → Neutral	$11 → $6
Oct-11-23	Initiated	H.C. Wainwright	Buy	$10
Mar-30-23	Initiated	Mizuho	Buy	$9
Feb-24-23	Initiated	Goldman	Buy	$10
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15

Nov-15-24 09:55AM	Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-12-24 04:01PM	Erasca Reports Third Quarter 2024 Business Updates and Financial Results (GlobeNewswire)
Nov-05-24 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-24-24 08:00AM	Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise (GlobeNewswire)
Sep-25-24 08:00AM	Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium (GlobeNewswire) +8.09%
08:00AM	Loading…
Aug-29-24 08:00AM	Erasca to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-24 10:53PM	ERAS Stock Earnings: Erasca Misses EPS for Q2 2024 (InvestorPlace) +7.92%
04:01PM	Erasca Reports Second Quarter 2024 Business Updates and Financial Results (GlobeNewswire)
Jun-18-24 12:14PM	Erasca kicks off Phase III trial for naporafenib combo therapy in melanoma (Clinical Trials Arena)
08:00AM	Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma (GlobeNewswire)
Jun-04-24 09:55AM	Should You Buy Erasca, Inc. (ERAS) After Golden Cross? (Zacks)
May-29-24 08:00AM	Erasca to Present at Upcoming Investor Conferences in June (GlobeNewswire)
May-21-24 04:05PM	Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
May-17-24 07:14AM	Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs (MT Newswires) +6.49%
05:51AM	Erasca restructures; Novartis moves to complete MorphoSys deal (BioPharma Dive)
05:31AM	Loading…
05:31AM	Erasca lays off 18% while swapping out KRAS program for fresh anti-tumor options (FierceBiotech.com)
04:11AM	Erasca Prices $160 Million Common Stock Offering (MT Newswires)
May-16-24 08:02PM	Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise (GlobeNewswire)
08:00PM	Erasca Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire)
May-08-24 11:55PM	ERAS Stock Earnings: Erasca Misses EPS for Q1 2024 (InvestorPlace) -8.84%
04:01PM	Erasca Reports First Quarter 2024 Business Updates and Financial Results (GlobeNewswire)
May-07-24 08:00AM	Erasca to Present at the Bank of America Health Care Conference (GlobeNewswire)
Apr-24-24 04:05PM	Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-23-24 12:00PM	Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Apr-01-24 04:56PM	Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:31AM	Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ... (GuruFocus.com)
Mar-27-24 10:53PM	ERAS Stock Earnings: Erasca Beats EPS for Q4 2023 (InvestorPlace)
08:30PM	Erasca Announces $45 Million Oversubscribed Private Placement Financing (GlobeNewswire)
04:01PM	Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results (GlobeNewswire)
Feb-14-24 08:00AM	Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials (GlobeNewswire)
08:00AM	Loading…
Feb-01-24 08:00AM	Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-03-24 08:00AM	Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 01:34PM	3 Penny Stocks Youll Regret Not Buying Soon: December Edition (InvestorPlace) -5.08%
Dec-11-23 08:00AM	Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma (GlobeNewswire)
Nov-28-23 08:00AM	Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway (GlobeNewswire) -11.38%
Nov-09-23 04:01PM	Erasca Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire) -8.64%
Nov-08-23 08:00AM	Erasca to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-12-23 11:28AM	Insiders Are Betting Millions on These 2 Stocks Heres Why You Might Want to Follow Their Lead (TipRanks)
Oct-10-23 03:56PM	Why Shares of Erasca Are Jumping Tuesday (Motley Fool) +13.18%
Sep-19-23 08:00AM	Erasca to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:00AM	Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-29-23 08:00AM	Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors (GlobeNewswire)
Aug-10-23 04:01PM	Erasca Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire) +11.92%
Jul-12-23 06:35AM	Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation (Simply Wall St.)
Jun-22-23 04:01PM	Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma (GlobeNewswire) -7.96%
Jun-15-23 06:22AM	Jonathan Lim Spends US$275k On Erasca Stock \ (Simply Wall St.)
Jun-06-23 10:53AM	Erasca Puts Certain Pipeline Programs On Chopping Block To Focus On Programs With Encouraging Activity Signals (Benzinga) -8.18%
Jun-05-23 04:01PM	Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline (GlobeNewswire) +14.19%
Jun-01-23 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
May-31-23 08:00AM	Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor (GlobeNewswire)
May-25-23 05:00PM	Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting (GlobeNewswire) -5.07%
09:01AM	With 42% stake, Erasca, Inc. (NASDAQ:ERAS) seems to have captured institutional investors' interest (Simply Wall St.)
May-16-23 08:00AM	Erasca Further Strengthens Business Leadership with Two Key Promotions (GlobeNewswire)
May-15-23 04:01PM	Erasca Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
May-02-23 08:00AM	Erasca to Present at the Bank of America Securities 2023 Health Care Conference (GlobeNewswire)
May-01-23 08:00AM	Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma (GlobeNewswire)
Apr-26-23 05:00PM	Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-25-23 08:00AM	Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma (GlobeNewswire)
Apr-18-23 09:00AM	Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-12-23 07:07AM	Daily Vickers Top Buyers & Sellers for 04/12/2023 (Argus Research)
Apr-10-23 08:00AM	Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development (GlobeNewswire) -8.83%
Mar-31-23 06:19AM	Trade Alert: The Co-Founder Of Erasca, Inc. (NASDAQ:ERAS), Jonathan Lim, Has Just Spent US$284k Buying A Few More Shares (Simply Wall St.)
Mar-30-23 04:21AM	6 analyst picks of the day: Walmart stock pops, Fluence upped to Buy \| Pro Recap (Investing.com)
Mar-23-23 04:01PM	Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Mar-14-23 04:31PM	Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting (GlobeNewswire)
Feb-01-23 08:00AM	Erasca to Present at the Guggenheim Oncology Conference 2023 (GlobeNewswire)
Jan-16-23 06:19AM	We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth (Simply Wall St.)
Jan-11-23 03:04PM	11 Best All-Time Low Stocks To Buy Now (Insider Monkey) +8.00%
Jan-04-23 08:00AM	Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-22 08:00AM	Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors (GlobeNewswire)
Dec-17-22 07:28AM	Co-Founder Jonathan Lim Just Bought A Handful Of Shares In Erasca, Inc. (NASDAQ:ERAS) (Simply Wall St.)
Dec-16-22 07:15AM	Erasca, Inc.'s (NASDAQ:ERAS) recent 16% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Dec-13-22 08:00AM	Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors (GlobeNewswire)
Dec-09-22 10:00AM	Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering (Benzinga) -22.30%
07:34AM	Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib (GlobeNewswire)
07:32AM	Erasca Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire)
Nov-30-22 08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination (GlobeNewswire) +6.34%
Nov-22-22 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-14-22 09:55AM	Wall Street Analysts Predict a 126% Upside in Erasca, Inc. (ERAS): Here's What You Should Know (Zacks)
Nov-09-22 04:01PM	Erasca Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +16.62%
Oct-20-22 08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination (GlobeNewswire)
Oct-12-22 08:00AM	Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium (GlobeNewswire)
Sep-26-22 08:00AM	Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022 (GlobeNewswire)
Sep-09-22 08:31AM	Erasca to Present at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Sep-08-22 11:08AM	Erasca Touts Promising Early Data From Lead Cancer Programs (Benzinga) -11.28%
Sep-07-22 04:05PM	Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials (GlobeNewswire) +6.21%
Aug-24-22 08:00AM	Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors (GlobeNewswire)
Aug-23-22 09:55AM	Here's Why Erasca, Inc. (ERAS) Looks Ripe for Bottom Fishing (Zacks) +5.08%
08:00AM	Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers (GlobeNewswire)
Aug-19-22 09:55AM	Wall Street Analysts See an 111% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High? (Zacks) -5.56%
Aug-11-22 04:05PM	Erasca Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -11.12% +15.35%
Aug-08-22 09:29AM	Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation (Simply Wall St.)
Aug-03-22 09:55AM	Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 244%: Here's is How to Trade (Zacks)
Jul-27-22 06:00PM	Erasca, Inc. (ERAS) Gains But Lags Market: What You Should Know (Zacks)
Jul-21-22 06:00PM	Erasca, Inc. (ERAS) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jul-18-22 06:15PM	Erasca, Inc. (ERAS) Gains As Market Dips: What You Should Know (Zacks) +8.33%
09:55AM	Wall Street Analysts See a 288% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High? (Zacks)
08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination (GlobeNewswire)
Jul-12-22 06:00PM	Erasca, Inc. (ERAS) Stock Moves -0.32%: What You Should Know (Zacks)
Jul-06-22 06:15PM	Erasca, Inc. (ERAS) Outpaces Stock Market Gains: What You Should Know (Zacks) +5.52%

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Erasca Foundation	Affiliate	Nov 15 '24	Proposed Sale	2.72	8,333	22,648		Nov 15 02:46 PM
Erasca Foundation	Affiliate	Oct 15 '24	Proposed Sale	2.68	8,333	22,306		Oct 15 02:29 PM
Erasca Foundation	Affiliate	Sep 16 '24	Proposed Sale	2.89	8,333	24,090		Sep 16 04:11 PM
Erasca Foundation	Affiliate	Aug 15 '24	Proposed Sale	2.59	8,333	21,619		Aug 15 01:14 PM
Casdin Alexander W.	Director	May 21 '24	Buy	2.27	80,000	181,920	573,974	May 22 06:57 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ERAS

Erasca Inc

Upgrade your FINVIZ experience